Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ConocoPhillips
COP
|
+$3.16B |
| 2 |
Merck
MRK
|
+$2.72B |
| 3 |
SLB Ltd
SLB
|
+$1.62B |
| 4 |
Target
TGT
|
+$1.6B |
| 5 |
General Mills
GIS
|
+$930M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$2.81B |
| 2 |
Blackrock
BLK
|
+$2.57B |
| 3 |
US Bancorp
USB
|
+$1.84B |
| 4 |
M&T Bank
MTB
|
+$808M |
| 5 |
Huntington Bancshares
HBAN
|
+$595M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.45% |
| 2 | Financials | 11.9% |
| 3 | Healthcare | 10.6% |
| 4 | Consumer Discretionary | 9.01% |
| 5 | Industrials | 8.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CHMI
3401
Cherry Hill Mortgage Investment Corp
CHMI
$85.2M
| $49.5K | ﹤0.01% |
15,001
| – | – |
|
3402
Sagimet Biosciences
SGMT
$442M
| $48.9K | ﹤0.01% |
+15,000
| New | +$62.9K |
|
3403
RenovoRx
RNXT
$47.8M
| $48.7K | ﹤0.01% |
49,232
| – | – |
|
3404
Lightpath Technologies
LPTH
$784M
| $48.6K | ﹤0.01% |
24,173
| – | – |
|
|
HURA
3405
TuHURA Biosciences
HURA
$136M
| $48.5K | ﹤0.01% |
15,000
| – | – |
|
3406
MarketWise
MKTW
$53.6M
| $48.3K | ﹤0.01% |
4,889
| – | – |
|
|
IVAC
3407
DELISTED
Intevac Inc
IVAC
| $47.5K | ﹤0.01% |
11,887
| – | – |
|
3408
Genasys
GNSS
$78.3M
| $47.5K | ﹤0.01% |
20,918
| – | – |
|
|
ELEV
3409
DELISTED
Elevation Oncology
ELEV
| $47.1K | ﹤0.01% |
181,694
+57,513
| +46% | +$32.8K |
|
3410
Research Solutions
RSSS
$74.3M
| $47K | ﹤0.01% |
18,069
| – | – |
|
3411
Veritone
VERI
$103M
| $46.5K | ﹤0.01% |
20,000
| – | – |
|
3412
Kopin
KOPN
$693M
| $46.5K | ﹤0.01% |
49,841
-76,051
| -60% | -$112K |
|
3413
Smart Sand
SND
$186M
| $45.2K | ﹤0.01% |
17,439
| – | – |
|
3414
Verrica Pharmaceuticals
VRCA
$90.2M
| $44K | ﹤0.01% |
9,951
+5,586
| +128% | +$36.1K |
|
3415
Outlook Therapeutics
OTLK
$180M
| $44K | ﹤0.01% |
36,060
+12
| +0% | +$21 |
|
3416
Zevia
ZVIA
$121M
| $43.2K | ﹤0.01% |
20,011
| – | – |
|
3417
Ovid Therapeutics
OVID
$435M
| $42.3K | ﹤0.01% |
135,487
-26,321
| -16% | -$16.2K |
|
3418
PetMed Express
PETS
$42.3M
| $41.9K | ﹤0.01% |
10,000
-99,186
| -91% | -$451K |
|
3419
Offerpad Solutions
OPAD
$17.3M
| $41.6K | ﹤0.01% |
2,504
-880
| -26% | -$19.2K |
|
3420
Grove Collaborative
GROV
$45.8M
| $41.2K | ﹤0.01% |
30,520
| – | – |
|
|
ORGN
3421
DELISTED
Origin Materials
ORGN
| $39.8K | ﹤0.01% |
2,001
+1
| +0.1% | +$27 |
|
3422
Marchex
MCHX
$84.2M
| $39.6K | ﹤0.01% |
24,313
| – | – |
|
3423
Richtech Robotics
RR
$371M
| $39.6K | ﹤0.01% |
+20,000
| New | +$49.2K |
|
3424
Intellicheck
IDN
$76.8M
| $39.3K | ﹤0.01% |
12,962
| – | – |
|
3425
CPI Aerostructures
CVU
$64.7M
| $38.8K | ﹤0.01% |
+11,173
| New | +$47.4K |
|
Similar funds
Charles Schwab's Q1 2025 Portfolio in Review
As of Q1 2025, Charles Schwab held 3,548 positions worth $533B, down 1.7% from $542B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2025: portfolio turnover was 3.6%. Charles Schwab opened 55 new positions and exited 74, leaving the 3,548-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 24% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2025 buy was iShares Currency Hedged MSCI Eurozone ETF: 7,259,426 shares worth $283M.
- Charles Schwab added most to ConocoPhillips in Q1 2025, an estimated $3.16B increase.
- Charles Schwab's biggest Q1 2025 reduction was Pfizer, cutting an estimated $2.81B.
- Charles Schwab fully exited Brookfield in Q1 2025, selling an estimated $218M.
- Charles Schwab's ten largest holdings make up 20% of its $533B portfolio in Q1 2025.
- Charles Schwab opened 55 new positions and closed 74 in Q1 2025.
- Charles Schwab's portfolio value fell 1.7% quarter-over-quarter to $533B.
Based on Charles Schwab's 13F filing for Q1 2025, filed 9 May 2025.